
Non Hodgkin Lymphoma (NHL) Global Market Report 2025
Description
Non Hodgkin Lymphoma (NHL) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non hodgkin lymphoma (nhl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Where is the largest and fastest growing market for non hodgkin lymphoma (nhl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non hodgkin lymphoma (nhl) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Markets Covered:1) By Type: B-Cell Lymphoma; T-Cell Lymphoma
2) By Treatment: Surgery; Stem Cell Transplant; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Chronic Lymphocytic Leukemia (CLL); Mantle Cell Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL); Anaplastic Large Cell Lymphoma (ALCL); Cutaneous T-Cell Lymphoma (CTCL); T-Cell Lymphoblastic Lymphoma; Adult T-Cell Leukemia/Lymphoma (ATLL)
Companies Mentioned: Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
This report focuses on non hodgkin lymphoma (nhl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non hodgkin lymphoma (nhl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non hodgkin lymphoma (nhl) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Markets Covered:1) By Type: B-Cell Lymphoma; T-Cell Lymphoma
2) By Treatment: Surgery; Stem Cell Transplant; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Chronic Lymphocytic Leukemia (CLL); Mantle Cell Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL); Anaplastic Large Cell Lymphoma (ALCL); Cutaneous T-Cell Lymphoma (CTCL); T-Cell Lymphoblastic Lymphoma; Adult T-Cell Leukemia/Lymphoma (ATLL)
Companies Mentioned: Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Table of Contents
200 Pages
- 1. Executive Summary
- 2. Non Hodgkin Lymphoma (NHL) Market Characteristics
- 3. Non Hodgkin Lymphoma (NHL) Market Trends And Strategies
- 4. Non Hodgkin Lymphoma (NHL) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market
- 5. Global Non Hodgkin Lymphoma (NHL) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Non Hodgkin Lymphoma (NHL) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Non Hodgkin Lymphoma (NHL) Market Growth Rate Analysis
- 5.4. Global Non Hodgkin Lymphoma (NHL) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Non Hodgkin Lymphoma (NHL) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Non Hodgkin Lymphoma (NHL) Total Addressable Market (TAM)
- 6. Non Hodgkin Lymphoma (NHL) Market Segmentation
- 6.1. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- B-Cell Lymphoma
- T-Cell Lymphoma
- 6.2. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgery
- Stem Cell Transplant
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- 6.3. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes of Administration
- 6.4. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other Distribution Channels
- 6.5. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Centers
- Other End Users
- 6.6. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of B-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia (CLL)
- Mantle Cell Lymphoma
- Burkitt Lymphoma
- Marginal Zone Lymphoma
- Primary Mediastinal B-Cell Lymphoma
- 6.7. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of T-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Peripheral T-Cell Lymphoma (PTCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Cutaneous T-Cell Lymphoma (CTCL)
- T-Cell Lymphoblastic Lymphoma
- Adult T-Cell Leukemia/Lymphoma (ATLL)
- 7. Non Hodgkin Lymphoma (NHL) Market Regional And Country Analysis
- 7.1. Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market
- 8.1. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 9. China Non Hodgkin Lymphoma (NHL) Market
- 9.1. China Non Hodgkin Lymphoma (NHL) Market Overview
- 9.2. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 10. India Non Hodgkin Lymphoma (NHL) Market
- 10.1. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Japan Non Hodgkin Lymphoma (NHL) Market
- 11.1. Japan Non Hodgkin Lymphoma (NHL) Market Overview
- 11.2. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. Australia Non Hodgkin Lymphoma (NHL) Market
- 12.1. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13. Indonesia Non Hodgkin Lymphoma (NHL) Market
- 13.1. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. South Korea Non Hodgkin Lymphoma (NHL) Market
- 14.1. South Korea Non Hodgkin Lymphoma (NHL) Market Overview
- 14.2. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Western Europe Non Hodgkin Lymphoma (NHL) Market
- 15.1. Western Europe Non Hodgkin Lymphoma (NHL) Market Overview
- 15.2. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. UK Non Hodgkin Lymphoma (NHL) Market
- 16.1. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Germany Non Hodgkin Lymphoma (NHL) Market
- 17.1. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. France Non Hodgkin Lymphoma (NHL) Market
- 18.1. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Italy Non Hodgkin Lymphoma (NHL) Market
- 19.1. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. Spain Non Hodgkin Lymphoma (NHL) Market
- 20.1. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Non Hodgkin Lymphoma (NHL) Market
- 21.1. Eastern Europe Non Hodgkin Lymphoma (NHL) Market Overview
- 21.2. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. Russia Non Hodgkin Lymphoma (NHL) Market
- 22.1. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. North America Non Hodgkin Lymphoma (NHL) Market
- 23.1. North America Non Hodgkin Lymphoma (NHL) Market Overview
- 23.2. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. USA Non Hodgkin Lymphoma (NHL) Market
- 24.1. USA Non Hodgkin Lymphoma (NHL) Market Overview
- 24.2. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. Canada Non Hodgkin Lymphoma (NHL) Market
- 25.1. Canada Non Hodgkin Lymphoma (NHL) Market Overview
- 25.2. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. South America Non Hodgkin Lymphoma (NHL) Market
- 26.1. South America Non Hodgkin Lymphoma (NHL) Market Overview
- 26.2. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Brazil Non Hodgkin Lymphoma (NHL) Market
- 27.1. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Middle East Non Hodgkin Lymphoma (NHL) Market
- 28.1. Middle East Non Hodgkin Lymphoma (NHL) Market Overview
- 28.2. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29. Africa Non Hodgkin Lymphoma (NHL) Market
- 29.1. Africa Non Hodgkin Lymphoma (NHL) Market Overview
- 29.2. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 30. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Company Profiles
- 30.1. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape
- 30.2. Non Hodgkin Lymphoma (NHL) Market Company Profiles
- 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis
- 31. Non Hodgkin Lymphoma (NHL) Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. GlaxoSmithKline plc
- 31.3. AbbVie Inc.
- 31.4. AstraZeneca plc
- 31.5. Takeda Pharmaceutical Company Limited
- 31.6. Bristol Myers Squibb Co.
- 31.7. Pfizer Inc.
- 31.8. Celgene Corporation
- 31.9. Sanofi S.A.
- 31.10. Janssen Pharmaceuticals Inc.
- 31.11. Johnson & Johnson
- 31.12. Biogen Idec
- 31.13. Boehringer Ingelheim GmbH
- 31.14. Eisai Co. Ltd.
- 31.15. Gilead Sciences
- 32. Global Non Hodgkin Lymphoma (NHL) Market Competitive Benchmarking And Dashboard
- 33. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market
- 34. Recent Developments In The Non Hodgkin Lymphoma (NHL) Market
- 35. Non Hodgkin Lymphoma (NHL) Market High Potential Countries, Segments and Strategies
- 35.1 Non Hodgkin Lymphoma (NHL) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Non Hodgkin Lymphoma (NHL) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Non Hodgkin Lymphoma (NHL) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
- 36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.